Understanding B7 Antigen: A Potential Drug Target for Cancer (P45435)

Target Name: B7 antigen

NCBI ID: P45435

B7 antigen

Other Name(s): B7 antigen

Understanding B7 Antigen: A Potential Drug Target for Cancer

B7 antigen, also known as nonspecified subtype B7 antigen, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the B7 superfamily, which includes B7.1, B7.2, B7.3 and B7.4 subfamily. B7 antigen plays an important role in immune responses, especially T cell-dependent antigen presentation.

The B7 antigen is composed of a single polypeptide chain with a molecular weight of approximately 120 kilodaltons. The antigen is highly specific and can bind to the receptors of a variety of cytokines, including PD-1, PD-L1, CTLA-4 and PD-L1. The expression level of the B7 antigen can vary due to a variety of factors. Such as the stage of immune response, the status of immune cells and the type of tumor, etc.

The role of B7 antigen in tumors has been extensively studied. Studies have shown that the expression level of B7 antigen is closely related to the prognosis of various tumors, especially melanoma and lung cancer. In addition, the expression level of B7 antigen is related to tumor invasiveness and metastasis. Therefore, studying the role of B7 antigen in tumor treatment has important clinical significance.

In addition to its use in tumor therapy, the B7 antigen may also be a potential drug target. Currently, a variety of drugs are available for treatment through receptors targeting the B7 antigen. These drugs include antibody drugs, peptide vaccines, and nucleic acid vaccines. These drugs can enhance the immune response and improve the survival rate of cancer patients.

Research on the B7 antigen has also attracted the attention of scientists. There are many researchers dedicated to studying the structure, function and relationship between B7 antigen and tumors. Through these studies, scientists can better understand how the B7 antigen works and how to target it with treatments.

Overall, the B7 antigen is a molecule with broad research prospects. With the continuous development of science and technology, more effective B7 antigen therapeutic drugs are expected to be developed in the future, providing better treatment options for tumor patients.

Protein Name: B7 Antigen (nonspecified Subtype)

The "B7 antigen Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B7 antigen comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets